← All indications
Granulomatosis with Polyangiitis
A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.
Drugs by status
Phase 4 trials (10)
Phase 3 trials (6)
Phase 2 trials (10)
Phase 1 trials (4)
Organizations
Organization Involved with Phase 4 Indications (11)
Organization Involved with Phase 3 Indications (30)
- Bristol-Myers Squibb
- AstraZeneca
- GlaxoSmithKline
- Nordic Pharma Group
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of Pennsylvania
- Johns Hopkins University
- Lund University
- University of Groningen
- University of Leicester
- University of Rochester
- University of South Florida
- Utrecht University
- University of Birmingham
- Mayo Clinic
- University of Colorado, Denver
- University of Copenhagen
- Food and Drug Administration
- University of Freiburg
- University of Lyon
- Institut mutualiste, Paris, France
- Fundació ACE
- Immune Tolerance Network
- National Center for Advancing Translational Science (NCATS)
- Dutch Health Care Insurance Board
- University of Helsinki
- Versus Arthritis
Organization Involved with Phase 2 Indications (11)
Organization Involved with Other Experimental Indications (3)